ŁŚŁukasz Światłowski

Łukasz Światłowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Łukasz Światłowski has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chemoembolization as a minimally invasive treatment of primary malignant liver cancer

    by Katarzyna Szklener, Weronika Kuryło, Anna Rodzajewska, Łukasz Światłowski, Tomasz Jargiełło, Sławomir Mańdziuk

    Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the most malignant neoplasms with high incidence and mortality in humans worldwide. The complex nature of the disease and its high resistance to systemic therapies result in poor prognosis for patients with advanced HCC. Case Report: In March 2017, the patient was admitted to the Department of Oncological Surgery, where a non-anatomical tumor resection was performed. Three years later, the patient developed a single change in segment 8 of the liver that was a relapse of the neoplastic process. Based on the Bracelon Criteria, the patient was qualified for the 1st stage of chemoembolization using the Seldinger method. In the presented patient as a result of the applied treatment, the neoplastic process was stabilized. Conclusion: The chemoembolization treatment that was applied to the presented patient turned out to be the correct treatment option. After only the first stage of chemoembolization, the patient regressed the neoplastic lesion.

  • SELECTING PATIENTS FOR EMBOLIZATION OF VARICOCELES BASED ON ULTRASONOGRAPHY

    by Izabela Dąbrowska, Łukasz Światłowski, Krzysztof Pyra, Tomasz Jargiełło, Agata Zarajczyk, i Maria Materek

  • Open Access

    IMPACT OF SYSTEMATIC AND MULTIDISCIPLINARY EVALUATION OF FMD PATIENTS ON NUMBER OF NEWLY REVEALED FMD LESIONS AND COMPLICATIONS -POLISH ARCADIA-POL STUDY

    by E. Warchol-Celinska, A. Prejbisz, K. Jozwik-Plebanek, E. Florczak, M. Januszewicz, I. Michalowska, L. Swiatlowski, M. Kabat, H. Janaszek-Sitkowska, L. Stryczynski, et al.

    Analysis of large cohorts of FMD patients allowed to reevaluate fibromuscular dysplasia (FMD) as a systemic arteriopathy. The aim of this analysis is to evaluate to what extent systematic and multidisciplinary evaluation of FMD patients results in novel FMD findings and reveals newly diagnosed vascular complications Out of 272 patients enrolled into ARCADIA-POL study since January 2015 (instituted on the basis of Polish-French collaboration) we present 192 patients with confirmed FMD in at least one vascular bed.. All patients underwent detailed clinical evaluation including ABPM, biochemical evaluation, biobanking, duplex Doppler of carotid and abdominal arteries and whole body angio-CT. All patients included in the study were evaluated by the multidisciplinary team including specialists in cardiology and hypertension, interventional cardiology, radiology, interventional radiology, neuroradiology and vascular surgery. Systematic evaluation of all 192 FMD patients included into the study revealed new FMD lesions in 61 (31.9 %) patients. Newly diagnosed vascular complications were found in 46 (24.0%) patients and in 2 patients more than one new vascular complications were revealed. Newly diagnosed aneurysms were found in 45 (32.4%) of patients and in 13 (6.8%) patients more than one aneurysms were found (Table). In 35 (18.2 %) FMD patients significant RAS was diagnosed.(Table). Systematic and multidisciplinary evaluation of FMD patients reveals a high incidence of previously unknown FMD lesions and newly diagnosed vascular complications.

  • Open Access

    Endovascular embolisation strategies for pulmonary arteriovenous malformations

    by Maryla Kuczyńska, Krzysztof Pyra, Łukasz Światłowski, Jan Sobstyl, Ewa Kuklik, Tomasz Jargiełło

    Purpose: To assess the immediate efficacy of distinct embolisation devices in the endovascular treatment of pulmonary arteriovenous malformations as well as to identify and analyse the possible determinants of the technical success of the procedure.Material and methods: Prospective analysis of 16 consecutive patients was carried out, who underwent transcatheter endovascular embolisation therapy for pulmonary arteriovenous malformations between 2005 and 2017. Pre- and post-procedural angiography studies were implemented to confirm the diagnosis and to evaluate the technical success defined as the complete occlusion of the feeding artery. Embolisation devices – coils, microcoils, occluders, or combination of the above – were used. All the patients were advised to conduct a follow-up computed tomography evaluation 12 months after the procedure.Results: A total of 40 pulmonary arteriovenous malformations (PAVMs) were observed and embolised. The immediate technical success was achieved in all (n = 40; 100%) treated PAVMs, as confirmed by the post-procedural angiographic result. The statistical analysis revealed no significant impact of the number of PAVMs per patient (p > 0.05), their angioarchitecture (p > 0.05), localisation within the lung (p > 0.05) or particular lobe (p > 0.05), and the selection of embolisation device (p > 0.05) on the procedural success rates. The procedure-related complication rate was equal to 6.25%.Conclusions: The immediate success rate of the transcatheter PAVM embolisation reached 100% in this study. The statistical model of logistic regression revealed no significant impact of the number of PAVMs per patient, their angioarchitecture, localisation, and distribution pattern, as well as device selection, on the immediate technical success of the procedure.